Abstract：Objective: To investigate the relationship between the serum lipid ratio and Chemerin level in patients with acute coronary syndrome (ACS) and the severity of coronary artery disease, to evaluate the clinical predictive value of the ratio of serum lipids and Chemerin level in patients with acute coronary syndrome (ACS). Methods: 230 patients who had done the coronary angiography in our hospital from July 2019 to January 2020 were selected that met the inclusion criteria, and their medical records and clinical examination data were collected and divided into ACS group (164 cases) and control group (66 cases). ACS group included unstable angina pectoris group (87 cases) and acute myocardial infarction group (77 cases). At the same time, Gensini score was divided into three groups: low group, medium group and high group. The differences of blood lipid ratio and Chemerin level among the groups and the correlation with the severity of coronary artery disease were analyzed. Results: Comprehensive analysis showed that the levels of TC / HDL-C, TG / HDL-C, non-HDL-C / HDL-C, LDL-C / HDL-C, LCI and Chemerin in ACS group were significantly higher than those in control group, and they were positively correlated with the severity of coronary artery disease (P<0.01), and Chemerin level was also positively correlated with TC / HDL-C, LDL-C / HDL-C, non-HDL-C / HDL-C (P<0.01). By establishing binary logistic regression model, Chemerin was found to be an independent risk factor for ACS (or = 1.03, P<0.01). The cut-off value of Chemerin in predicting ACS was 619.00ng/ml and the area under the ROC curve was 0.716( P<0.001,95%CI:0.649～0.783). Conclusion: The serum lipid ratio and Chemerin level in patients with acute coronary syndrome are significantly higher than those in the control group, and they are positively correlated with Gensini score. Meanwhile, the increase of Chemerin level can be used as an independent risk factor to predict ACS, and has high predictive value for ACS.
[1] Alon E,Robert P G,Eugene B.Updates on acute coronary syndrome: a review[J].JAMA Cardiol,2016,1(6):718~730. [2] Mohammed S R,Andrew J M,Kevin J W.Effects of dyslipidaemia on monocyte production and function in cardiovascular disease[J].Nat Rev Cardiol,2017,14(7):387~400. [3] Amsterdam E A,Wenger N K,Brindis R G,et al.2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines[J].Journal of the American College of Cardiology,2014,64(24):2645~2687. [4] Zhong S,Li L,Shen X,et al.An update on lipid oxidation and inflammation in cardiovascular diseases[J].Free Radic Biol Med,2019,144:266~278. [5] Hristov M.,Weber C.Myocardial infarction and inflammation: lost in the biomarker labyrinth[J].Circ Res,2015,116(5):781~783. [6] Akoumianakis I,Antoniades C.The interplay between adipose tissue and the cardiovascular system:is fat always bad[J].Cardiovasc Res,2017,113(9):999~1008. [7] G.K.Dimitriadis,J.Kaur,R.Adya,et al.Chemerin induces endothelial cell inflammation:activation of nuclear factor-kappa beta and monocyte-endothelial adhesion[J].Oncotarget,2018,(9):16678~16690. [8] Juan W,Jiajie W,Lan G,et al.Chemerin stimulates aortic smooth muscle cell proliferation and migration via activation of autophagy in VSMCs of metabolic hypertension rats[J].Am Transl Res,2019,11(3):1327~1342. [9] Jue J,Fan Y,Yuyun X,et al.Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis[J].Lipids Health Dis,2020,19(1):207.
2021, Vol. 27 
冀公网安备13080202000677号